LGC SARS-CoV-2 testing system granted emergency use authorisation

Published: 21-Apr-2021
Regulatory

The FDA’s authorisation enables qualified laboratories to address testing demands while providing significant economic advantage, LGC says

LGC’s SARS-CoV-2 real-time and end-point RT-PCR Test has been granted emergency use authorisation (EUA) by the FDA. It’s capable of processing up to 35,000 tests per day.

The FDA’s authorisation enables qualified laboratories to address testing demands while providing significant economic advantage, LGC says.

Mark Dearden, MD, LGC, Biosearch Technologies, said: “This tool is a game-changer in our fight against COVID-19. It offers the gold standard of PCR testing but with economics to support routine diagnostics at scale.”

Dearden continued: “The benefits of large-scale PCR testing can’t be underestimated. We know that extensive and frequent testing is a key tool for tracking and managing the spread of the virus. Used in concert with other point-of-need testing and continued vaccine rollout, the LGC solution can enhance our ability to fight the pandemic.”

The system is designed to be flexible and scalable, allowing organisations to meet evolving needs.

The company has been involved in the response to the COVID-19 pandemic since January 2020. It has a track record supporting the scientific and healthcare community with diagnostics for public health diseases as well as public health emergencies such as influenza, H1N1 (swine flu), Zika, and Ebola.

  • Companies:
  • LGC Group
See more

You may also like

Regulatory

LGC acquires Axolabs and invests in GMP manufacturing capacity for TNAs

Read more
LGC announced that it has acquired Axolabs, a leading Contract Research, Development and Manufacturing Organisation, specialising in the development of therapeutic nucleic acids (TNAs)

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

LGC acquires Axolabs and invests in GMP manufacturing capacity for TNAs

LGC announced that it has acquired Axolabs, a leading Contract Research, Development and Manufacturing Organisation, specialising in the development of therapeutic nucleic acids (TNAs)
Regulatory

LGC accelerates the development of new medicines

As regulatory pressure increases companies are saving time and money with effective extractables and leachables programmes
Regulatory

KKR partners with LGC to facilitate future expansion and growth

Will provide capital and operational support to facilitate future growth
Regulatory

LGC purchases South African testing firm Thistle QA

Expanding its clinical proficiency testing (PT) offering
Regulatory

ATCC adds new customer-driven format to its quality control standards portfolio

Makes it easier for industrial and pharmaceutical labs to test for product safety
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Subscribe now